Anticoagulants: dose control methods and inhibitors
These days, anticoagulants are in great demand. They are used as a prophylaxis for thromboembolic complications in various diseases and conditions in general therapeutic practice, cardiology, neurology, as well as obstetrics to manage high-risk pregnancies. The relevance of anticoagulants competent use has come to the fore in connection with the emergence of a new disease – COVID-19 and its serious complications such as developing thrombotic storm, in which the timely applied anticoagulant therapy is the key to the success of therapy. The risk of bleeding should be considered when using any anticoagulant. Age, impaired renal function and concomitant use of antiplatelet agents are common risk factors for bleeding. Moreover, only vitamin K antagonists and heparin have specific antidotes – vitamin K and protamine, respectively. Inhibitors of other anticoagulants are universal presented as inactivated or activated prothrombin complex concentrate and recombinant factor VIIa. Hemodialysis effectively reduces dabigatran concentration, activated charcoal is effective in the case of recent oral administration of lipophilic drugs. Research on new antidotes of currently available anticoagulants is under way, similar to testing of new types of anticoagulants that are sufficiently effective in preventing and treating thromboembolic complications with minimal risk of hemorrhagic. The main contraindication to anticoagulants use is the doctor's ignorance of the mechanisms of drug action and opportunities for suppressing its effect..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
Акушерство, гинекология и репродукция - 16(2022), 2, Seite 158-175 |
| Sprache: |
Russisch |
|---|
| Beteiligte Personen: |
V. O. Bitsadze [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Anticoagulants |
|---|
| doi: |
10.17749/2313-7347/ob.gyn.rep.2022.293 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ030938201 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ030938201 | ||
| 003 | DE-627 | ||
| 005 | 20230410105129.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230226s2022 xx |||||o 00| ||rus c | ||
| 024 | 7 | |a 10.17749/2313-7347/ob.gyn.rep.2022.293 |2 doi | |
| 035 | |a (DE-627)DOAJ030938201 | ||
| 035 | |a (DE-599)DOAJ820c4012d85b43ba91c9c580c4b52ef6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a rus | ||
| 050 | 0 | |a RG1-991 | |
| 100 | 0 | |a V. O. Bitsadze |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Anticoagulants: dose control methods and inhibitors |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a These days, anticoagulants are in great demand. They are used as a prophylaxis for thromboembolic complications in various diseases and conditions in general therapeutic practice, cardiology, neurology, as well as obstetrics to manage high-risk pregnancies. The relevance of anticoagulants competent use has come to the fore in connection with the emergence of a new disease – COVID-19 and its serious complications such as developing thrombotic storm, in which the timely applied anticoagulant therapy is the key to the success of therapy. The risk of bleeding should be considered when using any anticoagulant. Age, impaired renal function and concomitant use of antiplatelet agents are common risk factors for bleeding. Moreover, only vitamin K antagonists and heparin have specific antidotes – vitamin K and protamine, respectively. Inhibitors of other anticoagulants are universal presented as inactivated or activated prothrombin complex concentrate and recombinant factor VIIa. Hemodialysis effectively reduces dabigatran concentration, activated charcoal is effective in the case of recent oral administration of lipophilic drugs. Research on new antidotes of currently available anticoagulants is under way, similar to testing of new types of anticoagulants that are sufficiently effective in preventing and treating thromboembolic complications with minimal risk of hemorrhagic. The main contraindication to anticoagulants use is the doctor's ignorance of the mechanisms of drug action and opportunities for suppressing its effect. | ||
| 650 | 4 | |a bleeding | |
| 650 | 4 | |a antidote | |
| 650 | 4 | |a direct thrombin inhibitors | |
| 650 | 4 | |a factor xa inhibitors | |
| 650 | 4 | |a warfarin | |
| 650 | 4 | |a heparin | |
| 650 | 4 | |a low molecular weight heparins | |
| 650 | 4 | |a anticoagulants | |
| 653 | 0 | |a Gynecology and obstetrics | |
| 700 | 0 | |a E. V. Slukhanchuk |e verfasserin |4 aut | |
| 700 | 0 | |a J. Kh. Khizroeva |e verfasserin |4 aut | |
| 700 | 0 | |a M. V. Tretyakova |e verfasserin |4 aut | |
| 700 | 0 | |a V. I. Tsibizova |e verfasserin |4 aut | |
| 700 | 0 | |a N. R. Gashimova |e verfasserin |4 aut | |
| 700 | 0 | |a I. A. Nakaidze |e verfasserin |4 aut | |
| 700 | 0 | |a I. Elalamy |e verfasserin |4 aut | |
| 700 | 0 | |a J.-C. Gris |e verfasserin |4 aut | |
| 700 | 0 | |a A. D. Makatsariya |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Акушерство, гинекология и репродукция |d IRBIS LLC, 2019 |g 16(2022), 2, Seite 158-175 |w (DE-627)DOAJ000052302 |x 25003194 |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2022 |g number:2 |g pages:158-175 |
| 856 | 4 | 0 | |u https://doi.org/10.17749/2313-7347/ob.gyn.rep.2022.293 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/820c4012d85b43ba91c9c580c4b52ef6 |z kostenfrei |
| 856 | 4 | 0 | |u https://www.gynecology.su/jour/article/view/1319 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2313-7347 |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2500-3194 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 2022 |e 2 |h 158-175 | ||